Mads Holten-Andersen

Dr. Mads Holten-Andersen

Innlandet Hospital Trust
+1

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in Clinical Chemistry
Verified
Journal Article
Open access
CSCatharine M Sturgeon
Catharine M Sturgeon
MDMichael J Duffy
Michael J Duffy
USUlf-HåkAn Stenman
Ulf-HåkAn Stenman
HLHans Lilja
Hans Lilja
NBNils BrünNer
Nils BrünNer
EDEleftherios P Diamandis
Eleftherios P Diamandis
Background: Updated National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers in the clinic have been developed.Methods: Published reports relevant to use of tumor markers for 5 cancer sites—testicular, prostate, colorectal, breast, and ovarian—were critically reviewed.Results: For testicular cancer, α-fetoprotein, human chorionic gonadotropin, and lactate dehydrogenase are recommended for diagnosis/case finding, staging, prognosis determination, recurrence detection, and therapy monitoring. α-Fetoprotein is also recommended for differential diagnosis of nonseminomatous and seminomatous germ cell tumors. Prostate-specific antigen (PSA) is not recommended for prostate cancer screening, but may be used for detecting disease recurrence and monitoring therapy. Free PSA measurement data are useful for distinguishing malignant from benign prostatic disease when total PSA is <10 μg/L. In colorectal cancer, carcinoembryonic antigen is recommended (with some caveats) for prognosis determination, postoperative surveillance, and therapy monitoring in advanced disease. Fecal occult blood testing may be used for screening asymptomatic adults 50 years or older. For breast cancer, estrogen and progesterone receptors are mandatory for predicting response to hormone therapy, human epidermal growth factor receptor-2 measurement is mandatory for predicting response to trastuzumab, and urokinase plasminogen activator/plasminogen activator inhibitor 1 may be used for determining prognosis in lymph node–negative patients. CA15-3/BR27–29 or carcinoembryonic antigen may be used for therapy monitoring in advanced disease. CA125 is recommended (with transvaginal ultrasound) for early detection of ovarian cancer in women at high risk for this disease. CA125 is also recommended for differential diagnosis of suspicious pelvic masses in postmenopausal women, as well as for detection of recurrence, monitoring of therapy, and determination of prognosis in women with ovarian cancer.Conclusions: Implementation of these recommendations should encourage optimal use of tumor markers.

9 April 1999 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
Mads Holten-AndersenMads Holten-Andersen
Mads Holten-Andersen
GMG Murphy
G Murphy
HNHans J. Nielsen
Hans J. Nielsen
APA N Pedersen
A N Pedersen
ICI J Christensen
I J Christensen
RSR W Stephens
R W Stephens
A kinetic enzyme-linked immunosorbent assay (ELISA) for plasma tissue inhibitor of metalloproteinase (TIMP)-1 was developed in order to examine the potential diagnostic and prognostic value of TIMP-1 measurements in cancer patients. The ELISA enabled specific detection of total TIMP-1 in EDTA, citrate and heparin plasma. The assay was rigorously tested and requirements of sensitivity, specificity, stability and good recovery were fulfilled. TIMP-1 levels measured in citrate plasma (mean 69.2 ± 13.1 μg l–1) correlated with TIMP-1 measured in EDTA plasma (mean 73.5 ± 14.2 μg l–1) from the same individuals in a set of 100 healthy blood donors (Spearman’s rho = 0.62, P < 0.0001). The mean level of TIMP-1 in EDTA plasma from 143 patients with Dukes’ stage D colorectal cancer was 240 ± 145 μg l–1 and a Mann–Whitney test demonstrated a highly significant difference between TIMP-1 levels in healthy blood donors and colorectal cancer patients (P < 0.0001). Similar findings were obtained for 19 patients with advanced breast cancer (mean 292 ± 331 μg l–1). The results show that TIMP-1 is readily measured in plasma samples by ELISA and that increased levels of TIMP-1 are found in patients with advanced cancer. It is proposed that plasma measurements of TIMP-1 may have value in the management of cancer patients.

1 April 2004 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAnne-Sofie Schrohl
Anne-Sofie Schrohl
Mads Holten-AndersenMads Holten-Andersen
Mads Holten-Andersen
HPHarry A. Peters
Harry A. Peters
MLMaxine P. Look
Maxine P. Look
MGMarion E. Meijer-Van Gelder
Marion E. Meijer-Van Gelder
JFJohn A. Foekens
John A. Foekens
Purpose: In the present study, we investigated the association between tumor tissue levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prognosis in patients with primary breast cancer and analyzed whether TIMP-1 may be useful as a prognostic marker in combination with urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1). Experimental Design: In cytosolic extracts of 2984 primary breast tumors, total levels of TIMP-1 were determined using an established, validated ELISA. Levels of uPA and PAI-1 have previously been determined in the extracts. Results: Univariate survival analysis showed a significant relationship between higher levels of TIMP-1 (continuous log-transformed variable) and poor prognosis [recurrence-free survival (RFS), overall survival (OS); P < 0.001]. Performing isotonic regression analysis, we identified a cut point to classify tumors as TIMP-1-low or TIMP-1-high. Using this cut point, high levels of TIMP-1 were significantly associated with shorter survival in univariate analysis, both in the total patient group (RFS, OS; P < 0.001), in the node-negative subgroup (RFS, hazard ratio = 1.28, P = 0.006), and in the node-positive subgroup (RFS, hazard ratio = 1.43, P < 0.001). In multivariate analysis, including uPA and PAI-1, TIMP-1 was significantly associated with shorter RFS, both when included as a continuous log-transformed (P = 0.03) and as a dichotomized variable (P = 0.002). Conclusions: This study validates previous findings that tumor tissue levels of TIMP-1 are associated with prognosis in patients with primary breast cancer. It confirms that TIMP-1 may be useful as a prognostic marker in combination with uPA/PAI-1 and adds substantial positive information on the use of TIMP-1 as a prognostic marker in breast cancer.

1 June 2003 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
ASAnne-Sofie Schrohl
Anne-Sofie Schrohl
Mads Holten-AndersenMads Holten-Andersen
Mads Holten-Andersen
FSfred Sweep
fred Sweep
MSManfred Schmitt
Manfred Schmitt
NHNadia Harbeck
Nadia Harbeck
NBNils Brünner
Nils Brünner
A very broad definition of a tumor marker is: a tool that enables the clinician to answer clinically relevant questions regarding a cancer disease ([1][1]). However, most researchers in this field would probably prefer the following more specific definition of a tumor marker: a molecule, a process,

1 December 2006 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAnne-Sofie Schrohl
Anne-Sofie Schrohl
MGMarion E. Meijer-Van Gelder
Marion E. Meijer-Van Gelder
Mads Holten-AndersenMads Holten-Andersen
Mads Holten-Andersen
ICIb Jarle Christensen
Ib Jarle Christensen
MLMaxime P. Look
Maxime P. Look
JFJohn A. Foekens
John A. Foekens
Purpose: Only about 50% of metastatic breast cancer patients benefit from cytotoxic chemotherapy. Today, no validated markers exist for prediction of chemotherapy sensitivity/resistance in this patient group. Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been shown to protect against apoptosis, and the purpose of the present study was to test the hypothesis that tumors expressing high levels of TIMP-1 are protected against apoptosis-inducing agents and thus less sensitive to apoptosis-inducing chemotherapeutic drugs.

1 March 2003 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
PDF file
ASAnne-Sofie Schrohl
Anne-Sofie Schrohl
ICIb Jarle Christensen
Ib Jarle Christensen
APAnders N. Pedersen
Anders N. Pedersen
VJVibeke Jensen
Vibeke Jensen
HMHenning Mouridsen
Henning Mouridsen
Mads Holten-AndersenMads Holten-Andersen
Mads Holten-Andersen
The purpose of this study was to investigate the association between tumor tissue levels of total tissue inhibitor of metalloproteinases-1 (TIMP-1) and prognosis in patients with primary breast cancer and to analyze whether measurement of TIMP-1 in tumor extracts added prognostic information to that obtained from measurements of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 (PAI-1). An established sandwich enzyme-linked immunosorbent assay was thoroughly validated for the measurement of total TIMP-1 in tumor tissue extracts and used to determine levels of total TIMP-1 in 341 detergent-extracted tumor tissue samples from patients with primary breast cancer. The median age of the patients was 56 years (range, 29–75 years), and 164 were lymph node-negative, and 177 were lymph node-positive. The median follow-up time of the patients was 8.5 years (range, 7.3–11.3 years), and during follow-up 153 patients experienced recurrence of disease, and 136 patients died. In univariate survival analysis, we found a significant association between tumor tissue TIMP-1 level and both shorter recurrence-free survival (p = 0.0004) and shorter overall survival (p = 0.03). In multivariate survival analysis, higher tumor tissue TIMP-1 levels significantly and independently predicted shorter recurrence-free survival (p < 0.05, hazard ratios >1, comparing quartiles II–IV with I). In addition, we found that measurement of TIMP-1 levels added prognostic information to that obtained from measurement of PAI-1. In conclusion, high levels of TIMP-1 in tumor tissue extracts are significantly associated with a poor prognosis in patients with primary breast cancer. Furthermore TIMP-1 adds prognostic information to that obtained from PAI-1. However, further validation in independent data sets is needed.